Teva appoints former Dyax executive

Ivana Magovčević-Liebisch appointed SVP and head of corporate business development

JERUSALEM — Teva Pharmaceutical Industries has appointed a former executive from Dyax to its executive team, the Israeli generic drug maker said.

Teva announced the appointment of Ivana Magovčević-Liebisch as SVP and head of corporate business development, effective April 1. Magovčević-Liebisch served as EVP and COO for Dyax, a Burlington, Mass.-based drug company.

"Teva continues to build its premier leadership team, and we anticipate that Ivana, with her track record in partnering and licensing agreements and her extensive industry experience from R&D to commercial operations, will play an important role in the ongoing success of our business development programs," Teva group EVP human resources and chief integration officer Ika Abravanel said.


Login or Register to post a comment.